Tumour Necrosis Factor α Inhibitors during Spondylarthritis: Therapeutic Maintenance, Reasons, and Predictive Factors of Discontinuation (Data from RBSMR Registry)
Oumaima Idrissi Ouali(Sidi Mohamed Ben Abdellah University), Taoufik Harzy(Hôpital El Ayachi), R. Niamane(Hôpital Militaire Avicenne), Salma Mikou(Sidi Mohamed Ben Abdellah University), Imane El Mezouar, I. Ghozlani(Régie Autonome Multi Services D'Agadir), H. Hassikou, Moncef Maiouak(Centre Hospitalier Universitaire Hassan II), R. Bahiri(Centre Hospitalier Universitaire de Rabat-Salé), F. Allali(Délégation Paris 5), I. El Bouchti, Nessrine Akasbi(Centre Hospitalier Universitaire Hassan II), Rédouane Abouqal(Mohammed V University), Ihsane Hmamouchi(International University of Rabat), Saadia Janani(University of Hassan II Casablanca), A. El Maghraoui, Ahmed Bezza(Mohammed V University), L. Ichchou(Hôpital El Ayachi)
Cited by 0
Related Papers
Why we should definitely include intra-articular hyaluronic acid as a therapeutic option in the management of knee osteoarthritis: Results of an extensive critical literature review
|Seminars in Arthritis and Rheumatism|2018|164
High Prevalence of Hypovitaminosis D in Morocco: Relationship to Lifestyle, Physical Performance, Bone Markers, and Bone Mineral Density
|Seminars in Arthritis and Rheumatism|2008|154
Increase in bone mineral density of patients with spondyloarthropathy treated with anti-tumour necrosis factor α
|Annals of the Rheumatic Diseases|2003|122
Sarcopenia in rheumatoid arthritis: prevalence, influence of disease activity and associated factors
|Rheumatology International|2017|114